Taisho Pharmaceutical Co., Ltd.

Yoshihisa Shirasaki

Masato Takahashi

Hiroshi Ohta

Hiroaki Tanaka

Tsuyoshi Shibata

Takahiro Oi

Tetsuo Takayama

Fumihito Ushiyama

Masato Hayashi

Shuji Yamamoto

Naoya Ono

Nagaaki Sato

Kazunari Sakagami

Shigeru Tokita

Yoshinori Sekiguchi

Yuki Shimizu

Akito Yasuhara

Makoto Hamada

Fumiyasu Shiozawa

Shoichi Kuroda

Yusuke Oka

Daisuke Matsuda

Kenichi Kawabe

Kumi Abe

Yuko Araki

Xiang-Min Sun

Youichi Shimazaki

Akira Hiratate

Tsuyoshi Busujima

Kanako Iwakiri

Chie Koizumi

Sota Kato

There are provided compounds having a superior PHD2 inhibitory effect that are represented by general formula (I'): (in the above-mentioned general formula (I&#x2032;),W, Y, R, R, R, and Yare as described hereinabove), or pharmaceutically acceptable salts thereof.

Partially saturated nitrogen-containing heterocyclic compound

Provided are novel compounds that bind to FKBP12 or pharmaceutically acceptable salts thereof, as well as new therapeutics useful in the prevention or treatment of alopecia which comprise those compounds or pharmaceutically acceptable salts thereof. Specifically, compounds represented by formula (1) [where Rrepresents either the following formula (2) or (3)] or pharmaceutically acceptable salts thereof are provided.

Azole derivative

There are provided compounds represented by the following general formula (I) or pharmaceutically acceptable salts of thereof, which have a superior monoacylglycerol acyltransferase 2 inhibitory action: wherein wherein

Nitrogen-containing condensed heterocyclic compound

The present invention aims to provide novel compounds of formula [I] or pharmaceutically acceptable salts thereof that are based on a glycine uptake inhibiting action and which are useful in the prevention or treatment of such diseases as schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsory disorder, social anxiety disorder, posttraumatic stress disorder, specific phobia, acute stress disorder, etc.), depression, drug addiction, spasm, tremor, and sleep disorder: 

Glycine transporter inhibiting substances

Growing community of inventors

Toshima-ku, Japan

Yoshihisa Shirasaki